What is Accelerate Diagnostics?
Accelerate Diagnostics, Inc. is a specialized in vitro diagnostics company focused on providing advanced solutions for the rapid diagnosis of serious infections. Operating across the United States, Europe, and the Middle East, the company's flagship offering is the Accelerate Pheno system. This innovative platform is designed for the swift identification and antibiotic susceptibility testing of pathogens commonly associated with severe or health care-associated infections, including both gram-positive and gram-negative organisms. By accelerating the diagnostic process, Accelerate Diagnostics aims to enable clinicians to make more informed treatment decisions faster, potentially improving patient outcomes and combating antimicrobial resistance.
How much funding has Accelerate Diagnostics raised?
Accelerate Diagnostics has raised a total of $17M across 2 funding rounds:
Debt
$2M
Share Placement
$15M
Debt (2020): $2M with participation from PPP
Share Placement (2024): $15M, investors not publicly disclosed
Key Investors in Accelerate Diagnostics
PPP
Public-Private Partnership
What's next for Accelerate Diagnostics?
The recent major strategic investment positions Accelerate Diagnostics for a new phase of expansion and technological advancement. With enterprise-level funding, the company is poised to scale its operations, further develop its diagnostic platforms, and potentially broaden its market penetration. This strategic capital injection is likely intended to bolster research and development efforts, enhance manufacturing capabilities, and strengthen its commercial infrastructure to meet the growing demand for rapid and accurate infectious disease diagnostics. The company's focus on critical care diagnostics suggests a strategic alignment with global health priorities, particularly in combating antibiotic resistance.
See full Accelerate Diagnostics company page
